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in neighbouring endemic areas. However, substantial 
work remains to be done to harmonise and validate 
collected data. Currently, a major concern is the 
interpretation of molecular data because of the high 
diversity of the K13 gene: except for four mutations 
(C580Y, R539T, R543I, and Y493H), no clinical or in-vitro 
data have been associated with the other K13 mutant 
alleles.1,3 We believe that the scientiﬁ c community 
working on artemisinin resistance should now create 
a consortium around a K13 reference centre that could 
take over the management and data validation, the 
harmonisation of molecular biology techniques, the 
provision of control samples, and the organisation of 
a quality assurance system, to recommend the best 
therapeutic options—a prerequisite to move eﬀ ectively 
toward malaria elimination.
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Rotavirus vaccines roll-out in resource-deprived regions
Rotaviruses cause 30–50% of severe diarrhoea cases 
in children younger than 5 years, leading to about 
450 000 deaths every year.1 Infections during the ﬁ rst 
months of life are protective against symptomatic 
reinfections later on, setting the stage for vaccine 
development.2,3 The existence of four major genotypes—
G1[P8], G2[P4], G3[P8], and G4[P8]—created a great 
challenge because in-vitro studies suggested that 
antibodies to a speciﬁ c type neutralised only that type, 
raising the question of whether it would be necessary 
for a vaccine to include all common genotypes. 
During the 1990s the ﬁ rst licensed vaccine, Rotashield 
(Wyeth Laboratories, Collegeville, PA, USA), which 
contained an attenuated simian and three simian–
human reassortant strains of the virus, showed that 
70–90% of cases of severe rotavirus disease could 
potentially be prevented in lower-middle-income and 
high-income countries with vaccination.4 However, 
intestinal intussusception was induced in about one 
in 11 000 children who received the vaccine, leading 
to its withdrawal and posing a large challenge for new 
candidate vaccines because future trials needed to 
include 60 000 children to reasonably assure safety.5,6 
Post-licensure studies of the second-generation 
vaccines Rotarix (GlaxoSmithKline, Brentford, UK), 
which contains a single human attenuated strain, 
and RotaTeq (Merck, Kenilworth, NJ, USA) based on 
ﬁ ve human-bovine reassortant strains, suggest an 
acceptable class eﬀ ect risk for intestinal intussusception 
of somewhere between one in 20 000 and one in 
100 000 individuals.7 Importantly, both vaccines 
showed high eﬃ  cacy (more than 80%) against severe 
rotavirus disease in prelicensure studies5,6 and against 
several predominating genotypes. As trials were 
progressively done in various regions worldwide, it 
became clear that protective eﬃ  cacy for both vaccines 
was lower in resource-deprived countries than in high-
income countries8 and that eﬃ  cacy might not be the 
same among serotypes and genotypes, especially 
against G2[P4].5,9
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First licensed in 2006, these vaccines have been 
progressively introduced worldwide and dozens of 
eﬀ ectiveness trials, done mostly in high or middle-high 
income countries, have conﬁ rmed eﬃ  cacy rates reported 
in prelicensure trials. A major unanswered question 
is how eﬀ ective these vaccines will be in real-world 
scenarios in the poorest regions of the world (where 
diarrhoea mortality is at its highest) and in the presence 
of varied circulating types. Children might be infected in 
their ﬁ rst months of life in these regions (where a ﬁ rst 
infection is not as protective as in higher-income regions) 
such that children develop several severe episodes of 
rotavirus disease throughout their ﬁ rst years.3,10 Vaccine 
eﬀ ectiveness could be substantially lower in these 
regions, and, thus, meticulous pro spective studies are 
essential for policy decisions and for the potential design 
and assessment of new vaccine strategies. 
In The Lancet Infectious Diseases, Naor Bar-Zeev and 
colleagues11 report results of the second eﬀ ectiveness 
study to be done in Africa (Blantyre, Malawi). In the 
ﬁ rst study, Michelle Groome and colleagues12 showed 
57% (95% CI 40–68) eﬀ ectiveness against rotavirus 
diarrhoea that required a minimum of overnight 
hospital admission in children in South Africa younger 
than 2 years who were vaccinated at 6 and 14 weeks 
of life. Bar-Zeev and colleagues11 report 64% (24–83) 
eﬀ ectiveness for reduction of emergency room visits 
(compared with rotavirus test-negative controls) for 
rotavirus in children younger than 5 years (94% of 
samples tested from children younger than 2 years) 
using an accelerated 6 and 10 week of age schedule 
with the monovalent human rotavirus vaccine. Early 
eﬀ ect was documented with roughly 10% reductions 
every year in rotavirus detection rates in infants during 
their ﬁ rst and second years of age, and an overall rate 
reduction of near 15% after 2 years for all children 
younger than 5 years. Genotype G2[P4] was the most 
commonly detected (25% of samples tested), but the 
vaccine had a lower non-signiﬁ cant eﬀ ectiveness point 
estimate of 53% (95% CI –28 to 83) for G2[P4] than it 
did for G1[P8] (82%, 42–95), strongly suggesting lower 
eﬀ ectiveness against this genotype. 
That data for vaccine eﬀ ectiveness in Malawi are 
similar to, if not better than, those for other eﬃ  cacy trials 
is good news and ﬁ ndings can probably be extrapolated 
to regions with similar socioeconomic conditions. 
Diﬀ erential serotype and genotype eﬀ ectiveness will 
have to be continuously monitored and the search for 
even better vaccines and strategies must continue. 
Although, the natural history of rotavirus infection 
and disease in low-resource regions10 suggests that 
oral vaccines that mimic protection conferred by 
natural infections might have reached their maximum 
eﬀ ectiveness, this ﬁ gure is still substantial and vaccines 
could potentially prevent nearly 300 000 deaths of 
infants and children every year.
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In The Lancet Infectious Diseases, Shruthi Ravimohan 
and colleagues1 investigate whether immunological 
proﬁ les before and after antiretroviral therapy (ART) 
can distinguish patients co-infected with HIV and 
tuberculosis who develop tuberculosis-associated 
immune reconstitution inﬂ ammatory syndrome (IRIS) 
from those who do not develop this disorder and those 
who have early mortality. The investigators noted 
decreased pre-ART concentrations of several pro-
inﬂ ammatory cytokines in patients with tuberculosis-
associated IRIS (eg, interleukin [IL]-6 adjusted odds ratio 
[OR] per 1 log10 increase 0·40 [95% CI 0·18–0·89]), which 
resurged during the disease. After ART initiation, the 
most prominent changes in patients with tuberculosis-
associated IRIS were reported for cytokines related to 
innate immunity (eg, IL-6: adjusted OR 1·7 [95% CI 
1·2–2·5] and tumour necrosis factor [TNFα: 1·5 [1·0–2·2]), 
whereas recovery of the CD4 T-cell compartment was 
similar to that shown in control participants who 
survived without a diagnosis of tuberculosis-associated 
IRIS.
These ﬁ ndings seem to challenge the fundamental 
role of T cells in patients with tuberculosis-associated 
IRIS. Findings from early key reports pointed towards an 
overproduction of inﬂ ammatory T-helper-1 cytokines, 
such as interferon-γ, as being the driving force behind 
tuberculosis-associated IRIS.2 Lately, however, increasing 
evidence is emerging implicating the innate immune 
system in this syndrome.
Why is it that so many studies of tuberculosis-
associated IRIS report diﬀ erent or even conﬂ icting 
observations? In truth, tuberculosis-associated IRIS 
is a disease with many faces. Even when guidelines 
proposed by the International Network For The Study of 
HIV-Associated IRIS are used,3 patients diagnosed with 
tuberculosis-associated IRIS still present with symptoms 
that widely vary in type, severity, and timing.4 As such, 
the clinical picture of this disease might not be uniform 
across diﬀ erent studies, which could lead to observations 
becoming just as heterogeneous as the disease itself. 
For example, Ravimohan and colleagues now show the 
importance of the study of tuberculosis-associated IRIS 
during the actual IRIS event, when the inﬂ ammatory 
process is peaking. The increase in IL-6 concentrations 
between baseline and 4 weeks of ART in patients with 
tuberculosis-associated IRIS was much more pronounced 
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Tuberculosis-associated immune reconstitution inﬂ ammatory 
syndrome: a manifestation of adaptive or innate immunity? 
Published Online
February 9, 2015
http://dx.doi.org/10.1016/
S1473-3099(15)70026-5
See Articles page 429
El
isa
be
th
 S
ch
ne
id
er
/L
oo
k A
t S
cie
nc
es
/S
cie
nc
e 
Ph
ot
o 
Li
br
ar
y
